Streetbeat News

MAIA

MAIA Biotechnology, Inc.

https://www.MAIABiotech.com

Industry

Biotechnology

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Open

2.13

Mkt cap

54M

Volume

357K

High

2.29

P/E Ratio

-1.57

52-wk high

5.99

Low

1.80

Div yield

N/A

52-wk low

0.82

MAIA Biotechnology has secured $2.44 million in a private placement to fund the manufacturing of THIO for its Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC) and for working capital.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 7:43 am

MAIA Biotechnology announced that its abstract on second-generation THIO prodrugs has been accepted for presentation at the ENA 2024 Symposium. The company will present preclinical study results of its new telomere-targeting molecules, MAIA-2021-20 and MAIA-2022-12.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:34 pm

MAIA Biotechnology reports promising interim survival data from its Phase 2 trial of THIO, a telomere-targeting treatment for advanced non-small cell lung cancer. The trial shows improved survival rates, with some patients surpassing 12 months of survival. Full efficacy results are expected later this year.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 10:02 am

MAIA Biotechnology will present new Phase 2 clinical trial data at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will include updates on response rates and survival follow-up from the THIO-101 trial, which involves the lead candidate THIO combined with cemiplimab for advanced NSCLC patients.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 12:34 pm

MAIA Biotechnology announced promising long-term benefits from its Phase 2 THIO-101 trial for advanced non-small-cell lung cancer patients. The trial, which combines MAIA's THIO with Regeneron's cemiplimab, shows high efficacy and low toxicity. Despite positive results, MAIA's stock is down 14.25%.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 2:38 pm

SAP SE (NYSE:SAP) shares rose 5.9% in pre-market trading despite missing earnings and sales estimates for Q2. Other notable pre-market movers include Nature’s Miracle Holding Inc. (NASDAQ:NMHI), Volato Group, Inc. (NYSE:SOAR), and Frequency Electronics, Inc. (NASDAQ:FEIM) among gainers, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ) and MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) among losers.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 9:29 am

MAIA Biotechnology reports positive Phase 2 results for its lung cancer treatment THIO, showing safety, efficacy, and ongoing benefits in patients with advanced non-small cell lung cancer (NSCLC). The treatment, combined with cemiplimab (Libtayo®), has been well tolerated with lower toxicity compared to standard treatments.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 8:12 am

GameStop shares fell over 22% after releasing worse-than-expected Q1 results and filing to sell up to 75 million shares. The company reported net sales of $881.8 million, missing the consensus estimate of $995.3 million, and a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share. Other stocks moving significantly include Trinity Place Holdings, Leafly Holdings, Venus Concept, Asensus Surgical, Faraday Future, Geron Corporation, and more.

Portfolio Pulse from Avi Kapoor

June 07, 2024 | 5:07 pm

MAIA Biotechnology has announced the validation of clinical and regulatory pathways for its telomere-targeting cancer therapies following the FDA approval of Geron's Imetelstat. This development is significant for MAIA's future prospects in cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 4:31 pm

MAIA Biotechnology has announced significant year-to-date achievements, including clinical progress of its lead candidate THIO, a first-in-class cancer telomere targeting agent for non-small cell lung cancer (NSCLC). The company has secured over $12 million in funding, with $7.4 million raised in Q2'24. THIO has shown exceptional efficacy in Phase 2 clinical trials, with a 38% overall response rate and a median progression-free survival of 5.5 months, outperforming current standard-of-care treatments.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.